# Hims & Hers Health

Type: Company (HIMS)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/hims-hers-health
Canonical HTML page: https://getbiobrief.com/entity/hims-hers-health

## Timeline

- **2026-03-09**: Settlement Reached — Both companies announce an end to litigation and the start of a strategic collaboration.
- **2025-Q1**: Supply Stabilization — Novo Nordisk increases supply of branded Wegovy, challenging the legal basis for compounding.
- **2024-05**: Hims Enters Market — Hims & Hers launches its compounded semaglutide offering at a lower price point.
- **2023-Q4**: Litigation Begins — Novo Nordisk starts filing lawsuits against compounding pharmacies for IP infringement.

## Recent coverage (3 stories)

### Alcon core EPS up 9% to $0.84; PowerVision charge $402M
2026-08-18 00:44:12 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Alcon posted 7% constant-currency sales growth and raised full-year core EPS guidance to 12-15% growth, but took a $402M noncash charge to discontinue PowerVision. Hims & Hers added branded weight-loss momentum with $753M revenue.
Full story: https://getbiobrief.com/story/bio-alcon-q2-2026-power-vision

### Hims & Hers Surges 41% on Landmark GLP-1 Supply Deal with Novo Nordisk
2026-03-10 00:20:37 · Sentiment: Positive · Impact: 7/10 · Sources: 3

Hims & Hers Health shares skyrocketed 41% following a strategic agreement with Novo Nordisk to distribute branded GLP-1 medications, including Ozempic, directly through its telehealth platform. The deal effectively ends a high-stakes patent dispute and transitions the company away from controversial compounded formulations toward FDA-approved branded therapies.
Full story: https://getbiobrief.com/story/hims-hers-novo-nordisk-glp1-partnership

### Hims & Hers and Novo Nordisk Settle GLP-1 Dispute, Launch Collaboration
2026-03-09 17:33:03 · Sentiment: Positive · Impact: 6/10 · Sources: 5

Hims & Hers Health and Novo Nordisk have settled their legal dispute regarding compounded weight loss medications, transitioning into a strategic collaboration. This agreement marks a significant shift in the GLP-1 market, moving from litigation to a partnership that could broaden access to semaglutide treatments.
Full story: https://getbiobrief.com/story/hims-hers-novo-nordisk-settlement-glp1

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.